Labcorp Holdings Inc.
Clinical Laboratory Services and Biopharma Laboratory ServicesFounded 1995- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Labcorp Holdings Inc.
Company History
Founded 1995 in Burlington, North Carolina
Last reviewed: 2025-07-15 · By Swet Parvadiya
$13.01 billion in annual revenue from processing approximately 280 million patient encounters, with a strategic bet that specialty testing and health system partnerships can outgrow the commoditization of routine laboratory services. That is Labcorp in 2024, a company that has spent three decades building the largest independent clinical laboratory network in the United States while navigating Medicare reimbursement cuts, technological disruption, and the 2023 spin-off of its clinical development business. Diagnostics Laboratories generated $10.31 billion (79.2% of revenue) with a 14.9% adjusted operating margin, while Biopharma Laboratory Services contributed $2.70 billion (20.8% of revenue) with a $7.9 billion backlog providing future visibility. CEO Adam Schechter has guided the company toward 5.4% revenue growth and 8.9% adjusted EPS growth in 2026, targets that assume successful execution of specialty testing expansion, health system partnership growth, and operational efficiency initiatives. The company employs 70,000 people, maintains an investment-grade balance sheet with $1.52 billion in cash and $5.05 billion in debt, and returns capital to shareholders through dividends and buybacks.
James Powell is an American healthcare entrepreneur who founded National Health Laboratories in the 1970s and grew it into one of the largest clinical laboratory companies in the United States through a series of acquisitions of independent local laboratories. National Health Laboratories merged with Roche Biomedical Laboratories in 1995 to form Laboratory Corporation of America Holdings (Labcorp), creating the second-largest independent clinical laboratory company in the US. Powell's strategy of industry consolidation and operational scale became the dominant model for the clinical laboratory services market.
Roche Holdings, the Swiss pharmaceutical and diagnostics conglomerate, contributed Roche Biomedical Laboratories to the 1995 merger that created Labcorp. As one of the world's largest healthcare companies, Roche brought scientific expertise, diagnostic technology, and international relationships to the merged entity. Roche maintained a significant equity stake in Labcorp post-merger and the relationship has continued to provide Labcorp with access to advanced testing technologies and companion diagnostic development partnerships.
James Powell founded National Health Laboratories, beginning a consolidation strategy that would acquire independent clinical laboratories across the United States. The company grew through the 1970s and 1980s, building operational scale and a national specimen collection network.
Roche Biomedical Laboratories and National Health Laboratories merged to create Laboratory Corporation of America Holdings. The combination created the second-largest independent clinical laboratory company in the United States, with Roche contributing scientific capabilities and international relationships while National Health provided operational scale and US market presence.
Labcorp expanded beyond routine testing through acquisitions that added pathology, cytology, and specialty laboratory capabilities. These investments began the company's transition from a commodity routine testing provider toward higher-margin, higher-complexity diagnostic services.
Labcorp acquired Dynacare, a Canadian laboratory services company, expanding the company's geographic footprint beyond the United States. The acquisition added laboratory operations in Canada and demonstrated Labcorp's interest in international expansion.
Labcorp acquired US Pathology and Esoterix, significantly expanding specialty and esoteric testing capabilities. Esoterix was a leading provider of complex endocrine and coagulation testing, while US Pathology added anatomic pathology services. These acquisitions deepened Labcorp's specialty testing menu and improved margins.
Labcorp acquired Orchid Cellmark, a provider of DNA testing services for forensic, paternity, and immigration applications. The acquisition expanded Labcorp's genetic testing capabilities and added government contract relationships.
Labcorp acquired LipoScience, a diagnostic company specializing in cardiovascular disease risk assessment through nuclear magnetic resonance (NMR) technology. The acquisition added proprietary NMR-based testing to Labcorp's cardiovascular menu.
Labcorp acquired Covance Inc. for approximately $6.1 billion in cash and stock, creating a combined company with $8.4 billion in pro forma revenue. The acquisition integrated Labcorp's diagnostic testing leadership with Covance's contract research organization capabilities, positioning the company across the healthcare continuum from drug development to patient diagnostics.
Labcorp acquired Sequenom, a molecular diagnostics company specializing in non-invasive prenatal testing (NIPT) and women's health genetic screening. The acquisition made Labcorp a leader in prenatal genetic testing and expanded reproductive health capabilities.
Adam Schechter was appointed President and CEO of Labcorp, bringing experience from Merck where he had led the company's global human health business. Schechter's appointment signaled a strategic focus on expanding specialty testing, building health system partnerships, and leveraging data analytics to improve health outcomes.
Labcorp acquired Personal Genome Diagnostics (PGDx), adding liquid biopsy and tissue-based genomic profiling capabilities for oncology. The acquisition strengthened Labcorp's position in precision medicine and companion diagnostic development for cancer therapies.
Labcorp spun off its clinical development and commercialization services business as Fortrea Holdings Inc., creating a more focused diagnostics and laboratory services company. The spin-off reversed the diversification strategy of the Covance acquisition, reflecting management's view that diagnostics and clinical development were distinct businesses with different capital requirements and growth profiles.
The company changed its legal name from Laboratory Corporation of America Holdings to Labcorp Holdings Inc., reflecting the company's operating brand and simplified corporate structure following the Fortrea spin-off. The name change aligned the legal entity with the consumer-facing brand.
Labcorp acquired select assets of Invitae, a genetic testing company, advancing its strategy to launch and scale specialty testing in oncology and rare diseases. The acquisition added genetic counseling capabilities, variant interpretation expertise, and a broad genetic test menu that complemented Labcorp's existing specialty portfolio.
Labcorp reported FY2025 revenue of $13.95 billion, up 7.2% from 2024, with more than 130 innovative new tests launched during the year. The company signed or closed 13 health system and regional laboratory transactions, expanded its Central Laboratory facility, and provided 2026 guidance for revenue of $14.61–$14.79 billion.
Labcorp acquired Covance to create an integrated healthcare diagnostics company spanning drug development and patient diagnostics. Covance was a leading contract research organization providing central laboratory services, toxicology, and clinical trial management. The acquisition was expected to generate annual cost synergies exceeding $100 million within three years.
Labcorp acquired Sequenom to strengthen its position in non-invasive prenatal testing (NIPT) and women's health genetic screening. Sequenom was a molecular diagnostics company with proprietary technology for prenatal genetic testing.
Labcorp acquired PGDx to add liquid biopsy and tissue-based genomic profiling capabilities for oncology. PGDx specialized in precision oncology diagnostics, including comprehensive genomic profiling for solid tumors.
Labcorp acquired select assets of Invitae, a genetic testing company, to advance its strategy to launch and scale specialty testing in oncology and rare diseases. The acquisition added genetic counseling capabilities, variant interpretation expertise, and a broad genetic test menu.
Labcorp acquired select assets of BioReference Health's diagnostic business to increase access to Labcorp's clinical laboratory services, with a focus on clinical diagnostics and reproductive and women's health.